# Fondaparinux

## Arixtra 2.5mg/0.5mL pre-filled syringe

| TAH Drug Code      | [IARI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IARI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Prevention of venous thromboembolism (VTE) in adult patients at high risk of venous thrombosis undergoing major orthopedic lower limb surgery， such as hip fracture surgery， major knee surgery， or hip replacement surgery. 2. Prevention of VTE in adult patients deemed at high risk of thromboembolic complications undergoing abdominal surgery， such as abdominal cancer surgery. 3. Treatment of adult patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI) who are not suitable for immediate (within 120 minutes) invasive treatment (PCI). 4. Treatment of acute coronary syndrome in ST-elevation myocardial infarction (STEMI) to prevent death and recurrent myocardial infarction in patients receiving thrombolytic therapy or those who are not planned to undergo any form of reperfusion therapy. 5. Used in combination with warfarin sodium for the treatment of acute deep vein thrombosis (DVT). 6. Used in combination with warfarin sodium for the treatment of acute pulmonary embolism (PE). 7. Treatment of acute symptomatic spontaneous lower limb superficial vein thrombosis in adults without concomitant deep vein thrombosis. |
| Dosing             | For patients undergoing lower extremity surgery or abdominal surgery， SC 2.5mg once daily for 5-9 days. The first dose must be gievn 6 hours after surgery and stop bleeding. For UA/NSTEMI， SC 2.5mg daily for 8 days or discharge. Maximum 8 days. For STEMI， IV 2.5mg as first dose， followed by SC 2.5mg once daily to 8 days or dischrage. Maximum 8 days. For DVT and PE， SC once daily with dose of 5mg for weight < 50kg， 7.5mg for weight between 50-100 kg and 10mg for weight beyond 100 kg， combination with warfarin sodium within 72 hours， for at least 5 days， up to 9 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | - Known hypersensitivity to fondaparinux or any of its excipients. - Clinically significant active bleeding. - Acute bacterial endocarditis. - Severe renal impairment with creatinine clearance less than 20 mL/min. - Body weight less than 50 kg in patients requiring prophylaxis for venous thromboembolism. - Thrombocytopenia associated with positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common ‧Dermatologic: Injection site reaction， Rash (7.5% ) ‧Other: Fever (13.6% ) Serious ‧Hematologic: Anemia (perioperative prophylaxis， 19.6%; extended prophylaxis， 1.5% )， Hemorrhage (2.2% to 3.4% )， Thrombocytopenia (0.04% to 0.2% (less than 50，000/mm(3)); 0.5% to 3% (50，000 to 100，000/mm(3)) ) ‧Immunologic: Anaphylaxis， Hypersensitivity reaction ‧Neurologic: Extradural intracranial hematoma， Non-traumatic spinal subdural hematoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| More Info          | [UpToDate](https://www.uptodate.com/contents/fondaparinux-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

